Mll partial tandem duplication and Flt3 internal tandem duplication in a double knock-in mouse recapitulates features of counterpart human acute myeloid leukemias - Wikidata - wikimedia - TriplyDB

Mll partial tandem duplication and Flt3 internal tandem duplication in a double knock-in mouse recapitulates features of counterpart human acute myeloid leukemias

Mll partial tandem duplication and Flt3 internal tandem duplication in a double knock-in mouse recapitulates features of counterpart human acute myeloid leukemias

http://www.wikidata.org/entity/Q28594733

about

Functions of flt3 in zebrafish hematopoiesis and its relevance to human acute myeloid leukemia.E3 ubiquitin ligase Cbl-b activates the p53 pathway by targeting Siva1, a negative regulator of ARF, in FLT3 inhibitor-resistant acute myeloid leukemia Echinomycin protects mice against relapsed acute myeloid leukemia without adverse effect on hematopoietic stem cells Two decades of leukemia oncoprotein epistasis: the MLL1 paradigm for epigenetic deregulation in leukemia.Identification of medium-sized copy number alterations in whole-genome sequencing.Identification of functional cooperative mutations of SETD2 in human acute leukemia.Targeting leukemia stem cells in vivo with antagomiR-126 nanoparticles in acute myeloid leukemia High frequency of additional gene mutations in acute myeloid leukemia with MLL partial tandem duplication: DNMT3A mutation is associated with poor prognosis.Eradicating acute myeloid leukemia in a Mll(PTD/wt):Flt3(ITD/wt) murine model: a path to novel therapeutic approaches for human disease.Toward personalized therapy in AML: in vivo benefit of targeting aberrant epigenetics in MLL-PTD-associated AML.MicroRNA-29b mediates altered innate immune development in acute leukemia.Ordering of mutations in acute myeloid leukemia with partial tandem duplication of MLL (MLL-PTD).NPMc+ cooperates with Flt3/ITD mutations to cause acute leukemia recapitulating human disease.In focus: MLL-rearranged leukemia.Mixed lineage leukemia protein in normal and leukemic stem cells.Molecular and Epigenetic Mechanisms of MLL in Human Leukemogenesis.Mechanisms of mixed-lineage leukemia.Mutations in epigenetic modifiers in acute myeloid leukemia and their clinical utility.Prognostic and biological significance of the proangiogenic factor EGFL7 in acute myeloid leukemia.Receptor tyrosine kinase Axl is required for resistance of leukemic cells to FLT3-targeted therapy in acute myeloid leukemia.Integration of Hedgehog and mutant FLT3 signaling in myeloid leukemia.DNMT3A Haploinsufficiency Transforms FLT3ITD Myeloproliferative Disease into a Rapid, Spontaneous, and Fully Penetrant Acute Myeloid Leukemia.Identification of a germline F692L drug resistance variant in cis with Flt3-internal tandem duplication in knock-in mice The Impact of FLT3 Mutations on the Development of Acute Myeloid Leukemias.Emerging molecular predictive and prognostic factors in acute myeloid leukemia.Sorafenib promotes graft-versus-leukemia activity in mice and humans through IL-15 production in FLT3-ITD-mutant leukemia cells.De novo activating mutations drive clonal evolution and enhance clonal fitness in KMT2A-rearranged leukemia.Epigenetic Regulators in the Development, Maintenance, and Therapeutic Targeting of Acute Myeloid Leukemia.

P2860

8d62a3414f22de111b333e344e0e7986a6c593ab eb353ac21fa5c256bc2299bb168dc5d635c18099

P248

Q33595837-48CED41E-A560-41B5-B79F-E730091FB638 Q33903412-DA0F9604-21AC-4B36-9DD5-197E4569984A Q34047867-8CA7FC35-D44D-4C4C-BBF3-54F4E0BF11BD Q35018755-BFE9F384-E849-4B1B-9254-176540ABC8B5 Q35168086-F0EBCB1F-B7F0-4D47-8A92-A01BA8E52718 Q35632973-3DC87D57-DA50-422B-97D7-0C34D94FB579 Q36248867-3FF24B6B-8C47-4349-A6B0-8AEB4DDBE296 Q36545112-3955F385-FEF1-4271-A53E-659D9AC677B3 Q37349410-F0D45D2F-D9E7-4A00-B951-D71125642C91 Q37394708-6F39FA6C-4753-423E-84F3-B4DDE09C19A3 Q37452181-20586F04-3F58-46AD-A437-9D2FF5CA1CAA Q37559783-FD92DCF7-A6CB-4B0B-9D43-2A75EFB74A29 Q37599556-AB022192-098A-43D3-B1D3-3B1C43C02019 Q38091585-7D7740F9-2B62-46C7-9948-964277E9F1F1 Q38100107-6C58B3F4-7942-42B2-B0E5-5BE5A96E4AB5 Q38161393-D2BE0DF1-69C3-4D2D-8D01-C4F99D4C471F Q38190545-333AAED4-037B-4612-8042-FF0EC25F0B59 Q38703904-E5F1A6CB-AC82-45FD-96D0-A4B8F2918BA2 Q38769960-F2A32A67-3BA8-4550-AE46-7F0BF419806F Q38853220-E431A307-D5DC-4291-833F-77E0206FF662 Q38865256-0E78E11E-B5C2-46FE-A5A5-8BCEE8E4F46E Q40832501-AC55268E-5672-4718-82FD-0E5AF95C1BEF Q42391590-D9B2282A-C06B-45E4-92DA-EE77DB1EA290 Q43070849-C42CDED4-C405-4982-BEDB-90D49E752A74 Q47670541-F3ED4D48-2CB8-465E-A7F5-EDA2B2488BD3 Q50066002-00C4836A-B23E-4B89-B1E6-EA22563BE479 Q52714487-0E9D97BB-72B8-4766-AE50-2D68DA4A4C23 Q55433291-3B79E1CA-4861-4401-9392-C578B76C0C37

P2860

Mll partial tandem duplication and Flt3 internal tandem duplication in a double knock-in mouse recapitulates features of counterpart human acute myeloid leukemias

http://www.wikidata.org/entity/Q28594733

description

2012 թուականի Օգոստոսին հրատարակուած գիտական յօդուած

@hyw

2012 թվականի օգոստոսին հրատարակված գիտական հոդված

@hy

artículu científicu espublizáu en 2012

@ast

im August 2012 veröffentlichter wissenschaftlicher Artikel

@de

scientific journal article

@en

vedecký článok (publikovaný 2012/08/02)

@sk

vědecký článek publikovaný v roce 2012

@cs

wetenschappelijk artikel (gepubliceerd op 2012/08/02)

@nl

наукова стаття, опублікована в серпні 2012

@uk

مقالة علمية (نشرت في 2-8-2012)

@ar

name

Mll partial tandem duplication ...... human acute myeloid leukemias

@ast

Mll partial tandem duplication ...... human acute myeloid leukemias

@en

Mll partial tandem duplication ...... human acute myeloid leukemias

@nl

type

label

Mll partial tandem duplication ...... human acute myeloid leukemias

@ast

Mll partial tandem duplication ...... human acute myeloid leukemias

@en

Mll partial tandem duplication ...... human acute myeloid leukemias

@nl

prefLabel

Mll partial tandem duplication ...... human acute myeloid leukemias

@ast

Mll partial tandem duplication ...... human acute myeloid leukemias

@en

Mll partial tandem duplication ...... human acute myeloid leukemias

@nl

P1433

Q28594733-9E3F4E48-8C92-48A3-AF46-7E4BA723E849

P1476

Q28594733-DA118E51-4239-4217-B260-6AC0AAB8C7C3

P2093

Q28594733-00527E53-B9BF-43D3-BB2A-A96839B276A8

Q28594733-149C04D2-4EB6-4ADD-AA97-9855C50AF6DC

Q28594733-206EFA35-BFA7-454A-BF0F-B2CDC69CED56

Q28594733-2A3ADFF0-5DF2-4C76-9D9F-EB5D2FF3F5E9

Q28594733-2EC3603D-D569-4923-95CB-E0BCD3DC1B95

Q28594733-4ACEE136-DA03-418B-8607-4D9FE2F60499

Q28594733-4D3C9135-9136-44A6-BE7A-F9E0B5C23E60

Q28594733-508AB425-F2E7-4102-8693-B06710B46A7A

Q28594733-67D3034B-8952-4F66-892E-ACDFCAEAE5D8

Q28594733-A8BEECD0-8C13-45DB-B508-7A4099DD3376

P2860

Q28594733-0593F1AD-F793-41C7-9ECD-FDC3F1414FA1

Q28594733-35DCB17A-B0C6-4C8E-A377-C1F96DCC6B2F

Q28594733-3D6FDF9F-6640-4166-B62B-AA2B13C96D65

Q28594733-4F9D4BA1-3557-4B2C-B2C7-8B6518255C67

Q28594733-51749E78-3B4D-43D8-BCD9-50B6039CCBD5

Q28594733-55BD5BAA-0F74-413B-9ABE-2F1B82D460D3

Q28594733-575599D9-46A7-484B-B675-62DA715F08F3

Q28594733-5C458BDB-ED7A-4571-83E2-CE1D6B793E71

Q28594733-6DD7D5D4-6DED-47BA-B231-68432202106B

Q28594733-75FBB4F7-0974-4D45-8DC9-6060865838ED

P304

Q28594733-CE3981A5-A58A-4B91-80CC-EA94B80B5135

P31

Q28594733-EA76C93A-39D1-4A45-B1CB-49674BC9D8F1

P3181

Q28594733-D3991E3C-0348-4696-BCED-5838DFB60912

P356

Q28594733-7F015942-A051-455F-A305-5C109456C65D

P407

Q28594733-56A87AFA-16D5-4F87-BD30-052A8671B46C

P433

Q28594733-4A36583B-D1F2-4817-BA54-B0A90968C1C5

P478

Q28594733-646B1245-5178-42A2-BA5E-D4DDC3E95EAD

P50

Q28594733-7CB4C9F9-93CD-4D0A-B540-E380E6A3E099

Q28594733-B23D97C5-EEBD-4A91-AD7C-3CC2D2A7632E

P577

Q28594733-62C848A9-9E84-4ABE-BAED-68D9F682AC3E

P5875

Q28594733-95327D80-F8FA-42A3-9DF7-8EB166A55DD1

P698

Q28594733-DCB84056-3F6C-4589-9183-FDE5AE710FFE

P921

Q28594733-A5466475-6A6F-43CC-B66B-6E479AB0F8E3

Q28594733-FE43F280-2DFE-4F64-B540-C451BF37549F

P932

Q28594733-C0C4FCFB-A7D1-4166-84ED-3ACE5CE53B09

P3181

P356

BLOOD-2012-03-415067

P1433

P1476

Mll partial tandem duplication ...... human acute myeloid leukemias

@en

P2093

Adrienne M. Dorrance

http://www.w3.org/2001/XMLSchema#string

Benjamin H. Lee

http://www.w3.org/2001/XMLSchema#string

Charlene Mao

http://www.w3.org/2001/XMLSchema#string

Chidimma Kalu

http://www.w3.org/2001/XMLSchema#string

Daniel A. Yanes

http://www.w3.org/2001/XMLSchema#string

David Jarjoura

http://www.w3.org/2001/XMLSchema#string

Elshafa H. Ahmed

http://www.w3.org/2001/XMLSchema#string

Gabriele G. Marcucci

http://www.w3.org/2001/XMLSchema#string

Gang Huang

http://www.w3.org/2001/XMLSchema#string

Kathleen K. McConnell

http://www.w3.org/2001/XMLSchema#string

P2860

Absence of the wild-type allele predicts poor prognosis in adult de novo acute myeloid leukemia with normal cytogenetics and the internal tandem duplication of FLT3: a cancer and leukemia group B study.

Prevalence and prognostic impact of NPM1 mutations in 1485 adult patients with acute myeloid leukemia (AML).

Impact of gene dosage, loss of wild-type allele, and FLT3 ligand on Flt3-ITD-induced myeloproliferation

MLL translocations, histone modifications and leukaemia stem-cell development

MLL-AF9-induced leukemogenesis requires coexpression of the wild-type Mll allele.

Mixed lineage leukemia: a structure-function perspective of the MLL1 protein.

PML/RARalpha and FLT3-ITD induce an APL-like disease in a mouse model

The presence of a FLT3 internal tandem duplication in patients with acute myeloid leukemia (AML) adds important prognostic information to cytogenetic risk group and response to the first cycle of chemotherapy: analysis of 854 patients from the Unite

Analysis of FLT3-activating mutations in 979 patients with acute myelogenous leukemia: association with FAB subtypes and identification of subgroups with poor prognosis.

Analysis of FLT3 length mutations in 1003 patients with acute myeloid leukemia: correlation to cytogenetics, FAB subtype, and prognosis in the AMLCG study and usefulness as a marker for the detection of minimal residual disease.

P304

1130–1136

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P3181

4608824

http://www.w3.org/2001/XMLSchema#string

P356

10.1182/BLOOD-2012-03-415067

http://www.w3.org/2001/XMLSchema#string

P407

P433

5

http://www.w3.org/2001/XMLSchema#string

P478

120

http://www.w3.org/2001/XMLSchema#string

P50

P577

2012-08-02T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

225275952

http://www.w3.org/2001/XMLSchema#string

P698

22674806

http://www.w3.org/2001/XMLSchema#string

P921

FMS-like tyrosine kinase 3

Lysine (K)-specific methyltransferase 2A

P932

3412333

http://www.w3.org/2001/XMLSchema#string